KDC-MN-296 – Kodiac biolabs

Plain-language summaryIntrigue 72 / 100

Mazdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Eli Lilly and out-licensed to Innovent Biologics for development in China. Mechanistically similar to cotadutide and the natural peptide oxyntomodulin, but with a fatty-acid extension supporting once-weekly rather than daily dosing. Phase 2 trials in Chinese type 2 diabetes and obesity populations showed dose-dependent weight loss and HbA1c reduction comparable to or exceeding semaglutide at higher dose tiers. Phase 3 trials are ongoing in China. It is shaping up to be the first dual GLP-1/glucagon agonist to reach a major market, beating its Western competitors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

55/100

Solid dual GLP-1/glucagon agonist with real Phase 2 human signal, but a crowded class and triple-agonist competition cap its ceiling

Look, mazdutide is a genuinely interesting peptide in a genuinely crowded lane. It’s a dual GLP-1/glucagon receptor agonist — modified glucagon backbone, GLP-1 activity grafted in, C18 fatty acid extension for once-weekly dosing — developed by Lilly and out-licensed to Innovent Biologics for the Chinese market. The mechanism does something single GLP-1 agonists don’t: the glucagon arm drives measurable thermogenesis and energy expenditure on top of the GLP-1-mediated appetite suppression, which is at least theoretically a better handle on weight loss than appetite alone.

Here’s the thing though. The dual GLP-1/glucagon mechanism isn’t new. Oxyntomodulin is the natural endogenous template. Cotadutide (AstraZeneca/Pfizer) ran into this space years ago. Survodutide from Boehringer Ingelheim is also in late development on the same dual axis. So mazdutide isn’t defining its category — its competing for second or third position in a class that retatrutide (triple GIP/GLP-1/glucagon) is already threatening to supersede entirely. On differentiation, the compound’s phase 2 data is encouraging — dose-dependent HbA1c reduction and weight outcomes at higher tiers that track with or slightly exceed semaglutide — but thats not the same as being best-in-class when tirzepatide and retatrutide exist.

We think the evidence base is legitimately respectable for where mazdutide sits developmentally. Phase 2 data are real, multi-site, and the DREAMS Phase 3 program in China is ongoing. There’s a clear human signal for the mechanism, which is more than most peptides in the library can claim. What we dont get is the certainty of full Phase 3 readout or the regulatory history that would push evidence quality into the 70s.

From a research bench standpoint, mazdutide is useful primarily as a reference compound for the long-acting dual GLP-1/glucagon format. Investigators studying the glucagon thermogenesis contribution, the energy expenditure differential versus pure GLP-1, or the pharmacokinetic profile of C18-extended dual agonists have a reason to reach for it. It’s not irreplaceable — survodutide and cotadutide cover overlapping ground — but it’s a credible tool in that niche.

Honestly, the compound’s story is hard to tell without returning to the question of where it sits relative to retatrutide. If triple agonists prove out in Phase 3 with the weight loss magnitude early data suggests, dual GLP-1/glucagon becomes a historical stepping stone rather than a destination. Mazdutide is worth watching, worth understanding, and a solid addition to a research library focused on incretin pharmacology. It’s just not the lead compound in that conversation anymore.

Novelty: 58
Mechanism promise: 73
In-category differentiation: 35
Evidence quality: 54
Translational signal: 62
Research bench value: 48

Rationale Mazdutide scores well on mechanism and translational signal — the glucagon-driven energy expenditure layer on top of GLP-1 appetite suppression is real pharmacology with Phase 2 HbA1c and weight data to back it — but differentiation is the key drag: cotadutide, survodutide, and above all retatrutide make mazdutide a follower in a class it doesn’t define. The compound’s China-centric development trajectory also limits global bench relevance.

GLP-1 / glucagon dual receptor agonist

A long-acting dual GLP-1 and glucagon receptor agonist; under development for obesity and type 2 diabetes.

Abstract

Mazdutide (IBI362, LY3305677; modified peptide with glucagon backbone and GLP-1 modifications; molecular weight approximately 4500 Da) is a dual GLP-1/glucagon receptor agonist developed by Eli Lilly and out-licensed to Innovent Biologics for development in China. The compound is structurally and mechanistically similar to cotadutide and oxyntomodulin, with C18 fatty acid extension for once-weekly dosing. Phase 2 trials in type 2 diabetes and obesity demonstrated dose-dependent HbA1c reduction and weight loss comparable to or exceeding semaglutide at higher dose tiers. Phase 3 trials are ongoing in China (DREAMS program) and US. The dual mechanism produces increased energy expenditure (glucagon effect) on top of the GLP-1 appetite suppression. Used as a reference long-acting dual GLP-1/glucagon agonist.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-296Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-296

Mazdutide

Abstract

Read the full monograph